Phillandas T. Thompson Purchases 5,000 Shares of Flamel Technologies S.A. (AVDL) Stock
Flamel Technologies S.A. (NASDAQ:AVDL) insider Phillandas T. Thompson bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was bought at an average cost of $9.36 per share, with a total value of $46,800.00. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Flamel Technologies S.A. (NASDAQ:AVDL) traded up 0.22% on Thursday, reaching $9.22. The company had a trading volume of 127,033 shares. The company has a 50-day moving average price of $9.04 and a 200-day moving average price of $9.83. Flamel Technologies S.A. has a 52-week low of $8.14 and a 52-week high of $14.15. The firm has a market capitalization of $369.57 million, a PE ratio of 9.74 and a beta of 1.39.
Flamel Technologies (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.14. The company had revenue of $46.30 million for the quarter, compared to the consensus estimate of $45.17 million. Flamel Technologies had a return on equity of 29.84% and a net margin of 21.13%. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts forecast that Flamel Technologies S.A. will post $1.16 EPS for the current fiscal year.
Several brokerages have recently weighed in on AVDL. Roth Capital set a $15.00 target price on Flamel Technologies and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Langenberg & Company reissued a “buy” rating and issued a $30.00 price target (up previously from $27.00) on shares of Flamel Technologies in a report on Thursday, September 7th. Ladenburg Thalmann Financial Services increased their price target on Flamel Technologies from $27.00 to $30.00 in a report on Thursday, September 7th. Finally, Zacks Investment Research raised Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Monday, July 17th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Flamel Technologies presently has a consensus rating of “Buy” and an average price target of $19.83.
Several large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio grew its position in shares of Flamel Technologies by 37.2% in the second quarter. Public Employees Retirement System of Ohio now owns 57,690 shares of the company’s stock valued at $636,000 after purchasing an additional 15,657 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Flamel Technologies in the second quarter valued at about $181,000. State Street Corp grew its position in shares of Flamel Technologies by 1.7% in the second quarter. State Street Corp now owns 31,782 shares of the company’s stock valued at $351,000 after purchasing an additional 523 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Flamel Technologies in the second quarter valued at about $24,100,000. Finally, Stifel Financial Corp grew its position in shares of Flamel Technologies by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock valued at $667,000 after purchasing an additional 2,500 shares during the last quarter. 69.09% of the stock is currently owned by institutional investors.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.